Research progress on STAT protein inhibitors in the treatment of lymphoma
10.16438/j.0513-4870.2020-1831
- VernacularTitle:靶向STAT蛋白的抑制剂在淋巴瘤治疗中的研究进展
- Author:
Qi-hong DENG
1
;
Zheng WANG
2
;
Xian-ming DENG
1
;
Li LI
1
Author Information
1. State-Province Joint Engineering Laboratory of Targeted Drugs from Natural Products, School of Life Sciences, Xiamen University, Xiamen 361102, China
2. College of Food and Biological Engineering, Jimei University, Xiamen 361021, China
- Publication Type:Research Article
- Keywords:
lymphoma;
STAT transcription factor;
antineoplastic agent;
rug screening;
targeted therapy
- From:
Acta Pharmaceutica Sinica
2021;56(3):703-710
- CountryChina
- Language:Chinese
-
Abstract:
The abnormal activation and mutation of signal transducer and activator transcription (STAT) proteins has been implicated in multiple lymphomas. The research discovery and clinical application of STATs inhibitors have become an important strategy for treating lymphoma. This review introduces the abnormal activation and mutation of STATs in multiple malignant lymphomas, and focuses on reviewing the latest screening strategies targeting STATs and its clinical application in the treatment of lymphoma, providing references for the further development of STATs inhibitors.
